Quarterly report pursuant to Section 13 or 15(d)

2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.10.0.1
2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Oct. 31, 2018
Jul. 31, 2018
Oct. 31, 2017
Jul. 31, 2017
Oct. 31, 2018
Oct. 31, 2017
Apr. 30, 2018
Property, Plant and Equipment [Line Items]              
Intangible assets $ 3,549,427       $ 3,549,427   $ 3,549,427
Impairment of intangible assets         0 $ 0  
Impairment of long-lived assets         $ 0 0  
U.S. federal income tax rate         21.00%    
Research and development costs 115,101   $ 515,458   $ 382,895 943,128  
Uninsured cash balances 518,000       518,000   772,000
Accumulated deficit (98,216,080)       (98,216,080)   $ (95,964,143)
Net loss $ (1,036,574) $ (1,215,363) $ (1,814,298) $ (1,688,415) $ (2,251,937) $ (3,502,713)  
SG Austria [Member]              
Property, Plant and Equipment [Line Items]              
Percentage investment in SG Austria 14.50%       14.50%    
Cell-in-a-Box [Member]              
Property, Plant and Equipment [Line Items]              
Intangible assets $ 1,549,427       $ 1,549,427    
Diabetes License [Member]              
Property, Plant and Equipment [Line Items]              
Intangible assets $ 2,000,000       $ 2,000,000